Investors

Overview

Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.

Recent News

DateTitle
06/22/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective June 21, 2018, the compensation committee of the company’s board of directors granted 8 new employees options to purchase an aggregate of 142,000 shares of the company’s common stock with a per share exercise price of $16.30, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencem... 
05/25/18Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., May 25, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that effective May 23, 2018, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 61,000 shares of the company’s common stock with a per share exercise price of $15.30, the closing trading price on the grant date.  The stock options were granted pursuant to the Coherus BioSciences, Inc. 2016 Employment Commencement... 
05/22/18Coherus Prices Public Offering of Common Stock
REDWOOD CITY, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS) today announced the pricing of its underwritten public offering of 5,172,413 shares of its common stock at a price to the public of $14.50 per share. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 775,861 shares of its common stock at the public offering pric... 
05/21/18Coherus Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., May 21, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced it has commenced an underwritten public offering of $75,000,000 of shares of its common stock. All of the shares of the common stock to be sold in the offering will be offered by Coherus. In addition, Coherus expects to grant the underwriters a 30-day option to purchase up to an additional $11,250,000 of shares of its common stock at the public offering price, less the underwriting d... 
View All

Upcoming Events

There are currently no events scheduled.
View All

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Coherus Biosciences Inc posts new information to the site. Just enter your e-mail address and click Submit.
 

CHRS (Common Stock)

ExchangeNASDAQ (US Dollar)
Price$14.90
Change (%) Stock is Down 0.3 (1.97%)
Volume12,632
Data as of 07/16/18 9:55 a.m. ET
Refresh quote
Data provided by Nasdaq. Minimum 15 minutes delayed.
Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
E-mail AlertsE-mail Alerts
Financial Tear SheetFinancial Tear Sheet